laurabbook@gmail.com

*June 2025* Targeted OncologyTM: How did the MARIPOSA trial (NCT04487080) assess patients receiving amivantamab (Rybrevant) plus lazertinib (Lacluze) vs osimertinib (Tagrisso) forinterstitial lung disease (ILD)? Xiuning Le, MD, PhD: I think it's based on both . Nowadays, for ILD in most of the clinical trials, they will take our investigator…

*June 2025* Abstract Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC,…

*July 2025* Highlights --Mutations were more easily detected in CSF than in plasma of NSCLC leptomeningeal metastasis. --Genes enriched in CSF are altered in multiple oncogenic signaling pathways. --CSF exhibits significantly greater copy number variations and missense mutations than plasma. --Furmonertinib combined with bevacizumab, and high-dose pemetrexed for IVC can…

*April 2025* In this podcast, clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. Listen here.

*May 2025* In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Mara Antonoff, Dr. Shankar Siva, and Dr. David Carbone. The case explores the role of ablative therapy for residual disease in patients with stage IV NSCLC. Listen here.

*September 2025* Abstract Introduction Patients with NSCLC harboring EGFR mutations (EGFRm) have high mortality. The third-generation tyrosine kinase inhibitor, osimertinib, is approved for first-line EGFRm NSCLC. We used longitudinal U.S. medical oncology databases to evaluate real-world overall survival (rwOS) and prognostic risk factor groups in advanced EGFRm NSCLC treated with…

*September 2025* Abstract Introduction Uncommon EGFR mutations comprise 10% to 20% of all EGFR mutations in NSCLC and generally report reduced responsiveness to EGFR tyrosine kinase inhibitors (TKIs). Lazertinib, a third-generation EGFR-TKI, has found efficacy in common EGFR mutations, but its potential in uncommon mutations remains unexplored. This study investigated the efficacy and safety of lazertinib…

*May 2025* Scientists behind the phase III randomized, controlled AENEAS2 clinical trial said their results point to a new front-line treatment option for patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC). The trial’s principal investigator, Shun Lu, MD, PhD, said that aumolertinib with platinum-pemetrexed chemotherapy demonstrated a…